Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
W. Martin Kast(University of Southern California), C J Melief(Leiden University), Daniel Kolakofsky(The Netherlands Cancer Institute), Arie C. Voordouw(The Netherlands Cancer Institute), Rob H. Meloen(The Netherlands Cancer Institute), Lisa Roux(The Netherlands Cancer Institute), Hans Blom(The Netherlands Cancer Institute), J Curren(The Netherlands Cancer Institute)
Cited by 328
Related Papers
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549